Mucous Membrane Compositions for Stable Thin Fluid Films
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for dry or dysfunctional mucous membranes are inadequate in providing safe, effective, and flexible means to improve the performance and stability of mucous membranes, particularly in conditions like dry eye, dry mouth, and respiratory tract issues, by altering the chemical and biophysical attributes of these membranes.
Innovation Solution
Compositions and methods that modify mucous membranes by changing their intrinsic chemical composition, viscoelastic properties, and biophysical attributes, using agents such as reducing agents, linkers, organic molecules, and polymers to interact with mucous membrane components, enhancing the stability and performance of thin fluid films.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for dry or dysfunctional mucous membranes, then some symptomatic relief may be achieved, but the treatments are inadequate in providing safe, effective, and flexible means to improve the performance and stability of mucous membranes
Solution Approach 1:
The patent modifies the chemical and biophysical attributes of mucous membranes by changing parameters such as surface charge, hydrophilicity, and molecular composition. Agents are applied to alter these parameters to improve membrane performance and stability in conditions like dry eye, dry mouth, and respiratory tract issues
Solution Approach 2:
The invention provides a universal approach that can be applied to multiple types of mucous membranes (ocular, gastrointestinal, respiratory, urogenital) and various disease states. The same basic methodology of modifying chemical and biophysical attributes can be used across different conditions and tissue types
2Stability of the object's composition
If agents are applied to modify mucous membrane chemical composition and biophysical attributes, then the stability and performance of thin fluid films are enhanced, but the complexity of treatment protocols increases
Solution Approach 1:
The treatment approach is segmented into distinct functional components: agents that modify chemical composition, agents that alter biophysical attributes, and carriers that deliver these modifications. This segmentation allows for systematic development and simplifies the overall treatment protocol by addressing each aspect separately
3Productivity
If the intrinsic chemical composition and biophysical features of mucous membranes are changed, then the interaction with topical agents is improved, but the risk of unwanted side effects increases
Solution Approach 1:
The patent uses intermediaries such as carriers and adjuvants that facilitate the desired interaction between modified mucous membranes and topical agents while minimizing harmful effects. These intermediaries act as buffers that control the interaction dynamics and reduce unwanted side effects
Data Source
AI summary
The present invention relates to methods and compositions for modifying mucous membranes. In particular, the present invention relates to treating diseases associated with mucous membranes by changing the intrinsic chemical composition and/or physical features of a target mucous membrane.